The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase Ib study of pembrolizumab (pembro) plus trastuzumab emtansine (T-DM1) for metastatic HER2+ breast cancer (MBC).
 
Adrienne Gropper Waks
Research Funding - Genentech (Inst); MacroGenics (Inst)
 
Tanya Keenan
Employment - 5AM Ventures (I)
Stock and Other Ownership Interests - Aeglea Biotherapeutics (I); Alnylam (I); Crinetics Pharmaceuticals (I); Trillium Therapeutics (I)
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Cyclacel; Merck (Inst)
 
Tianyu Li
No Relationships to Disclose
 
Nabihah Tayob
No Relationships to Disclose
 
Gerburg M. Wulf
Stock and Other Ownership Interests - Selecta Biosciences (I)
Research Funding - Merck
Patents, Royalties, Other Intellectual Property - Pin1 as a marker for abnormal cell growth Patent number: 8129131
 
Edward T. Richardson
No Relationships to Disclose
 
Elizabeth A. Mittendorf
Honoraria - Physicans' Education Resource
Consulting or Advisory Role - Genomic Health; Merck; Merck; Peregrine Pharmaceuticals; Sellas Life Sciences; TapImmune Inc.
Research Funding - AstraZeneca (Inst); EMD Serono (Inst); Galena Biopharma (Inst); Genentech/Roche (Inst); GlaxoSmithKline
 
Beth Overmoyer
Research Funding - Eisai (Inst); Genentech (Inst); GTx (Inst); Incyte (Inst)
Travel, Accommodations, Expenses - Novartis
 
Ian E. Krop
Employment - AMAG Pharmaceuticals (I)
Leadership - AMAG Pharmaceuticals (I)
Stock and Other Ownership Interests - AMAG Pharmaceuticals (I)
Honoraria - AstraZeneca; Celltrion; Genentech/Roche
Consulting or Advisory Role - Context Therapeutics; Daiichi Sankyo; Genentech/Roche; ION Pharma; Macrogenics; Merck; Novartis; Seagen; Taiho Pharmaceutical
Research Funding - Genentech (Inst); Pfizer (Inst)
 
Eric P. Winer
Stock and Other Ownership Interests - Verastem
Honoraria - Genentech/Roche; Genomic Health
Consulting or Advisory Role - Carrick Therapeutics; G1 Therapeutics; Genomic Health; GlaxoSmithKline; Jounce Therapeutics; Leap Therapeutics; Lilly; Seagen
Research Funding - Genentech (Inst); Novartis (Inst)
 
Eliezer Mendel Van Allen
Stock and Other Ownership Interests - ervaxx; Genome Medical; Microsoft; Syapse; Tango Therapeutics
Consulting or Advisory Role - ervaxx; Genome Medical; Illumina; InVitae; Janssen; Novartis; Roche; Syapse; Takeda; Tango Therapeutics; Third Rock Ventures
Speakers' Bureau - Illumina
Research Funding - Bristol-Myers Squibb; Novartis
Patents, Royalties, Other Intellectual Property - Patent on clinical interpretation algorithms using cancer molecular data (Inst); Patent on discovery of chromatin regulators as biomarkers of response to cancer immunotherapy (Inst); Patent on discovery of retained intron as source of cancer neoantigens (Inst)
Travel, Accommodations, Expenses - Roche/Genentech
 
Judith Agudo
Employment - Sana Biotechnology (I)
 
Sara M. Tolaney
Consulting or Advisory Role - Abbvie; AstraZeneca; Bristol-Myers Squibb; Celldex; Eisai; G1 Therapeutics; Genentech; Immunomedics; Lilly; Merck; NanoString Technologies; Nektar; Novartis; Odonate Therapeutics; Paxman; Pfizer; Puma Biotechnology; Sanofi; Seagen; Silverback Therapeutics
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Cyclacel (Inst); Eisai (Inst); Exelixis (Inst); Genentech/Roche (Inst); Immunomedics (Inst); Lilly (Inst); Merck (Inst); NanoString Technologies (Inst); Nektar (Inst); Novartis (Inst); Odonate Therapeutics (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Celldex; Eisai; Genentech/Roche; Immunomedics; Lilly; Merck; NanoString Technologies; Nektar; Novartis; Pfizer; Puma Biotechnology